The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present disclosure relates to the use of inositol-stabilized arginine silicate complexes (“ASI”) with the addition of free inositol (“I”) to form a composition ASI+I for improving cognitive functioning in humans, particularly video game players.

The present disclosure relates to the use of inositol-stabilized arginine silicate complexes (“ASI”) with the addition of free inositol (“I”) to form a composition ASI+I for improving cognitive functioning in humans, particularly video game players.

Embodiments provided herein include methods, compositions, and uses of aromatic alcohols to increase the potency of antifungal agents.

Embodiments provided herein include methods, compositions, and uses of aromatic alcohols to increase the potency of antifungal agents.

Provided is a liquid composition comprising a mixture of terpenes, at least one cannabinoid and an oil carrier. According to one embodiments, the mixture of terpenes comprises alpha-pinene, myrcene and caryophyllene and at least one additional terpene selected from the group consisting of limonene, terpinolene, linalool, geraniol, humulene, nerolidol, bisabolol and combinations thereof. According to a further embodiment, the mixture of terpenes comprises alpha-pinene, myrcene, caryophyllene, nerolidol and bisabolol, and at least one additional terpene selected from the group consisting of ocimene, limonene, linalool, and combinations thereof. According to a further embodiment, the mixture of terpenes comprises alpha-pinene, limonene, terpinolene and caryophyllene and optionally at least one additional terpene selected from the group consisting of beta-pinene, eucalyptol, geraniol and bisabolol, or combinations thereof.

Provided is a liquid composition comprising a mixture of terpenes, at least one cannabinoid and an oil carrier. According to one embodiments, the mixture of terpenes comprises alpha-pinene, myrcene and caryophyllene and at least one additional terpene selected from the group consisting of limonene, terpinolene, linalool, geraniol, humulene, nerolidol, bisabolol and combinations thereof. According to a further embodiment, the mixture of terpenes comprises alpha-pinene, myrcene, caryophyllene, nerolidol and bisabolol, and at least one additional terpene selected from the group consisting of ocimene, limonene, linalool, and combinations thereof. According to a further embodiment, the mixture of terpenes comprises alpha-pinene, limonene, terpinolene and caryophyllene and optionally at least one additional terpene selected from the group consisting of beta-pinene, eucalyptol, geraniol and bisabolol, or combinations thereof.

Provided is a liquid composition comprising a mixture of terpenes, at least one cannabinoid and an oil carrier. According to one embodiments, the mixture of terpenes comprises alpha-pinene, myrcene and caryophyllene and at least one additional terpene selected from the group consisting of limonene, terpinolene, linalool, geraniol, humulene, nerolidol, bisabolol and combinations thereof. According to a further embodiment, the mixture of terpenes comprises alpha-pinene, myrcene, caryophyllene, nerolidol and bisabolol, and at least one additional terpene selected from the group consisting of ocimene, limonene, linalool, and combinations thereof. According to a further embodiment, the mixture of terpenes comprises alpha-pinene, limonene, terpinolene and caryophyllene and optionally at least one additional terpene selected from the group consisting of beta-pinene, eucalyptol, geraniol and bisabolol, or combinations thereof.

The present invention provides for a method for the treatment of a respiratory disease, disorder or condition, or a viral infection or viral disease, disorder or condition in a subject, the method comprising the step of administering to the subject a medically active liquid in nebulized form by inhalation, wherein the medically active liquid comprises niclosamide or a pharmaceutically acceptable salt thereof and wherein the medically active liquid is administered in nebulized form using an inhalation device, and wherein the inhalation device used to administer the medically active liquid comprising the niclosamide or a pharmaceutically acceptable salt thereof is a soft-mist-inhaler.

The present invention provides for a method for the treatment of a respiratory disease, disorder or condition, or a viral infection or viral disease, disorder or condition in a subject, the method comprising the step of administering to the subject a medically active liquid in nebulized form by inhalation, wherein the medically active liquid comprises niclosamide or a pharmaceutically acceptable salt thereof and wherein the medically active liquid is administered in nebulized form using an inhalation device, and wherein the inhalation device used to administer the medically active liquid comprising the niclosamide or a pharmaceutically acceptable salt thereof is a soft-mist-inhaler.